スマートインスリンペンの市場規模 - 製品タイプ・接続タイプ・用途・流通チャネル別 - 地域別展望・競合戦略・セグメント予測 (～2033年)

世界のスマートインスリンペンの市場規模は、2033年にかけて10.69％のCAGRで推移し、20億5,411万米ドルの規模に成長すると予測されています。

COVID-19の間は病院や糖尿病センターを訪れる患者が減少した結果、スマートインスリンペンの処方数が減少しました。さらに、配送チェーンの問題により小売店での入手が困難になり、売上が減少しました。パンデミックに関連した景気減速は消費者のコスト意識を高め、高価な連結型インスリンペンの市場を縮小させました。

当レポートでは、世界のスマートインスリンペンの市場を調査し、市場概要、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

• 促進要因・抑制要因・機会・課題の分析
• COVID-19の市場への影響

第5章 市場変数と見通し

• SWOT分析
• PESTEL分析
• ポーターのファイブフォース分析
• ヒートマップ分析

第6章 競合情勢

• 製造拠点の分布・販売エリア・製品タイプ
• M&A・提携・製品発売・協力

第7章 世界のスマートインスリンペン市場：製品別

• 世界の市場規模のシェア・予測
• スマートインスリンペン
• 従来型ペン用アダプター

第8章 世界のスマートインスリンペン市場：接続タイプ別

• 世界の市場規模のシェア・予測
• Bluetooth
• USB

第9章 世界のスマートインスリンペン市場：用途別

• 世界の市場規模のシェア・予測
• 1型糖尿病
• 2型糖尿病

第10章 世界のスマートインスリンペン市場：流通チャネル別

• 世界の市場規模のシェア・予測
• 病院薬局
• オンライン販売
• 小売薬局
• 糖尿病クリニック/センター

第11章 世界のスマートインスリンペン市場の予測

• 市場規模・市場シェア

第12章 世界のスマートインスリンペン市場：製品タイプ別

• 市場規模・市場シェアの推移・予測

第13章 世界のスマートインスリンペン市場：接続タイプ別

• 市場規模・市場シェアの推移・予測

第14章 世界のスマートインスリンペン市場：用途別

• 市場規模・市場シェアの推移・予測

第15章 世界のスマートインスリンペン市場：流通チャネル別

• 市場規模・市場シェアの推移・予測

第16章 世界のスマートインスリンペン市場：地域別

• 市場規模・市場シェアの推移・予測
• アジア太平洋
• 欧州
• 中東・アフリカ
• 北米
• ラテンアメリカ

第17章 企業プロファイル

• Bigfoot Biomedical
• Diamesco Co. Ltd.
• Eli Lilly and Company
• Emperra GmbH
• Jiangsu Deflu Medical Device Co. Ltd.
• Medtronic plc
• Novo Nordisk A/S
• Pendiq
• Sanofi (Sanofi-Aventis US LLC)
• Ypsomed Holding AG
• その他

第18章 略語一覧

第19章 参考リンク

第20章 結論

第21章 調査範囲

Smart Insulin Pens Market Introduction and Overview

According to SPER market research, Smart Insulin Pens Market Size- By Product, By Connectivity Type, By Application, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Smart Insulin Pens Market is predicted to reach USD 2054.11 Million by 2033 with a CAGR of 10.69%.

Smart insulin pens provide an accessible option for exogenous insulin administration and diabetes treatment. It is a reusable injector pen that works with a simple app on a smartphone which allow for wireless data transfer to the app. This intelligent system keeps track of dosages and generates reports, useful notifications, and half-unit doses that are exact. In addition, it alerts patients whenever insulin is about to expire or reaches its temperature spectrum, allowing them to change the cartridge and provide diabetic information to the medical staff as needed.

There was a decrease in the number of prescriptions for smart insulin pens as a result of fewer patients visiting hospitals and diabetic centers during the COVID 19 pandemic. Additionally, the accessibility of these pens at retail stores was disrupted by problems in the delivery chain, which led to a decrease in sales. The pandemic-related economic slowdown made consumers more cost-conscious, which decreased the market for expensive connected insulin pens.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Product, By Connectivity Type, By Application, By Distribution Channel

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Bigfoot Biomedical, Diamesco Co. Ltd., Eli Lilly and Company, Emperra GmbH, Jiangsu Deflu Medical Device Co. Ltd., Medtronic plc, Novo Nordisk A/S, Pendiq, Sanofi (Sanofi-Aventis US LLC), Ypsomed Holding AG, and others.

Smart Insulin Pens Market Segmentation

By Product: Based on the Product, Global Smart Insulin Pens Market is segmented as; Smart Insulin Pens, Adaptors for Conventional Pens

By Application: Based on the Application, Global Smart Insulin Pens Market is segmented as; Type 1 Diabetes, Type 2 Diabetes

By Distribution Channel: Based on the Distribution Channel, Global Smart Insulin Pens Market is segmented as; Hospital Pharmacies, Online Sales, Retail Pharmacies, Diabetes Clinics/Centers

Table of Contents

1.Introduction

• 1.1.Scope of the report
• 1.2.Market segment analysis

2.Research Methodology

• 2.1.Research data source
  • 2.1.1.Secondary Data
  • 2.1.2.Primary Data
  • 2.1.3.SPER's internal database
  • 2.1.4.Premium insight from KOL's
• 2.2.Market size estimation
  • 2.2.1.Top-down and Bottom-up approach
• 2.3.Data triangulation

3.Executive Summary

4.Market Dynamics

• 4.1.Driver, Restraint, Opportunity and Challenges analysis
  • 4.1.1.Drivers
  • 4.1.2.Restraints
  • 4.1.3.Opportunities
  • 4.1.4.Challenges
• 4.2.COVID-19 Impacts of the Global Smart Insulin Pens Market

5.Market variable and outlook

• 5.1.SWOT Analysis
  • 5.1.1.Strengths
  • 5.1.2.Weaknesses
  • 5.1.3.Opportunities
  • 5.1.4.Threats
• 5.2.PESTEL Analysis
  • 5.2.1.Political Landscape
  • 5.2.2.Economic Landscape
  • 5.2.3.Social Landscape
  • 5.2.4.Technological Landscape
  • 5.2.5.Environmental Landscape
  • 5.2.6.Legal Landscape
• 5.3.PORTER's Five Forces
  • 5.3.1.Bargaining power of suppliers
  • 5.3.2.Bargaining power of buyers
  • 5.3.3.Threat of Substitute
  • 5.3.4.Threat of new entrant
  • 5.3.5.Competitive rivalry
• 5.4.Heat Map Analysis

6.Competitive Landscape

• 6.1.Global Smart Insulin Pens Market Manufacturing Base Distribution, Sales Area, Product Type
• 6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Smart Insulin Pens Market

7.Global Smart Insulin Pens Market, By Product (USD Million)

• 7.1.Global Smart Insulin Pens Market Value Share and Forecast, By Product, 2024-2033
• 7.2.Smart Insulin Pens
• 7.3.Adaptors for Conventional Pens

8.Global Smart Insulin Pens Market, By Connectivity Type (USD Million)

• 8.1.Global Smart Insulin Pens Market Value Share and Forecast, By Connectivity Type, 2024-2033
• 8.2.Bluetooth
• 8.3.USB

9.Global Smart Insulin Pens Market, By Application (USD Million)

• 9.1.Global Smart Insulin Pens Market Value Share and Forecast, By Application, 2024-2033
• 9.2.Type 1 Diabetes
• 9.3.Type 2 Diabetes

10.Global Smart Insulin Pens Market, By Distribution Channel (USD Million)

• 10.1.Global Smart Insulin Pens Market Value Share and Forecast, By Distribution Channel, 2024-2033
• 10.2.Hospital Pharmacies
• 10.3.Online Sales
• 10.4.Retail Pharmacies
• 10.5.Diabetes Clinics/Centers

11.Global Smart Insulin Pens Market Forecast, 2020-2033 (USD Million)

• 11.1.Global Smart Insulin Pens Market Size and Market Share

12.Global Smart Insulin Pens Market, By Product Type 2020-2033 (USD Million)

• 12.1.Global Smart Insulin Pens Market Size and Market Share By Product (2020-2026)
• 12.2.Global Smart Insulin Pens Market Size and Market Share By Product (2027-2033)

13.Global Smart Insulin Pens Market, By Connectivity Type, 2020-2033 (USD Million)

• 13.1.Global Smart Insulin Pens Market Size and Market Share By Connectivity Type (2020-2026)
• 13.2.Global Smart Insulin Pens Market Size and Market Share By Connectivity Type (2027-2033)

14.Global Smart Insulin Pens Market, By Application, 2020-2033 (USD Million)

• 14.1.Global Smart Insulin Pens Market Size and Market Share By Application (2020-2026)
• 14.2.Global Smart Insulin Pens Market Size and Market Share By Application (2027-2033)

15.Global Smart Insulin Pens Market, By Distribution Channel, 2020-2033 (USD Million)

• 15.1.Global Smart Insulin Pens Market Size and Market Share By Distribution Channel (2020-2026)
• 15.2.Global Smart Insulin Pens Market Size and Market Share By Distribution Channel (2027-2033)

16.Global Smart Insulin Pens Market, By Region, 2020-2033 (USD Million)

• 16.1.Global Smart Insulin Pens Market Size and Market Share By Region (2020-2026)
• 16.2.Global Smart Insulin Pens Market Size and Market Share By Region (2027-2033)
• 16.3.Asia-Pacific
  • 16.3.1.Australia
  • 16.3.2.China
  • 16.3.3.India
  • 16.3.4.Japan
  • 16.3.5.South Korea
  • 16.3.6.Rest of Asia-Pacific
• 16.4.Europe
  • 16.4.1.France
  • 16.4.2.Germany
  • 16.4.3.Italy
  • 16.4.4.Spain
  • 16.4.5.United Kingdom
  • 16.4.6.Rest of Europe
• 16.5.Middle East and Africa
  • 16.5.1.Kingdom of Saudi Arabia
  • 16.5.2.United Arab Emirates
  • 16.5.3.Rest of Middle East & Africa
• 16.6.North America
  • 16.6.1.Canada
  • 16.6.2.Mexico
  • 16.6.3.United States
• 16.7.Latin America
  • 16.7.1.Argentina
  • 16.7.2.Brazil
  • 16.7.3.Rest of Latin America

17.Company Profile

• 17.1.Bigfoot Biomedical
  • 17.1.1.Company details
  • 17.1.2.Financial outlook
  • 17.1.3.Product summary
  • 17.1.4.Recent developments
• 17.2.Diamesco Co. Ltd.
  • 17.2.1.Company details
  • 17.2.2.Financial outlook
  • 17.2.3.Product summary
  • 17.2.4.Recent developments
• 17.3.Eli Lilly and Company
  • 17.3.1.Company details
  • 17.3.2.Financial outlook
  • 17.3.3.Product summary
  • 17.3.4.Recent developments
• 17.4.Emperra GmbH
  • 17.4.1.Company details
  • 17.4.2.Financial outlook
  • 17.4.3.Product summary
  • 17.4.4.Recent developments
• 17.5.Jiangsu Deflu Medical Device Co. Ltd.
  • 17.5.1.Company details
  • 17.5.2.Financial outlook
  • 17.5.3.Product summary
  • 17.5.4.Recent developments
• 17.6.Medtronic plc
  • 17.6.1.Company details
  • 17.6.2.Financial outlook
  • 17.6.3.Product summary
  • 17.6.4.Recent developments
• 17.7.Novo Nordisk A/S
  • 17.7.1.Company details
  • 17.7.2.Financial outlook
  • 17.7.3.Product summary
  • 17.7.4.Recent developments
• 17.8.Pendiq
  • 17.8.1.Company details
  • 17.8.2.Financial outlook
  • 17.8.3.Product summary
  • 17.8.4.Recent developments
• 17.9.Sanofi (Sanofi-Aventis US LLC)
  • 17.9.1.Company details
  • 17.9.2.Financial outlook
  • 17.9.3.Product summary
  • 17.9.4.Recent developments
• 17.10.Ypsomed Holding AG
  • 17.10.1.Company details
  • 17.10.2.Financial outlook
  • 17.10.3.Product summary
  • 17.10.4.Recent developments
• 17.11.Others

18.List of Abbreviations

19.Reference Links

20.Conclusion

21.Research Scope